Abstract: Objective: To analyze the clinical efficacy of tripterygium glycosides combined with dupilumab in the treatment of atopic dermatitis (AD). Methods: AD patients treated in our hospital from February 2023 to February 2024 were included in the analysis. The control group received basic treatment plus dupilumab, while the tripterygium group was given tripterygium glycosides on the basis of the treatment regimen for the control group. The treatment response rate was compared between the two groups, with a ≥50% reduction in EASI score defined as a therapeutic response. Results: A total of 88 patients were treated, with 44 cases in each group. Three cases were lost to follow-up in the control group and 4 cases in the tripterygium group. The response rate of the tripterygium group was 90%, which was significantly higher than that of the control group (70.73%) (P＜0.05). The incidence of adverse reactions was 17.08% in the control group and 22.50% in the tripterygium group, with no statistically significant difference between the two groups (P＞0.05). After 4, 8, and 12 weeks of treatment, the EASI score, Itch-NRS score, IGA score, and DLQI score in both groups were lower than those before treatment; the reduction in the tripterygium group was more significant, and all differences were statistically significant (Ps＜0.05). Conclusions: The efficacy of tripterygium glycosides combined with dupilumab is superior to that of dupilumab alone in the treatment of AD, with no serious adverse reactions.

Key words: tripterygium glycosides wilfordii, dupilumab, atopic dermatitis, therapeutic responsiveness